MannKind Corporation Tech Stack

Biopharmaceutical company commercializing inhalable therapies for cardiometabolic and orphan lung diseases

Pharmaceutical Manufacturing Danbury, CT 501–1,000 employees Public Company

MannKind is a public biopharmaceutical company (Nasdaq: MNKD) focused on drug-device combination therapies for diabetes, pulmonary hypertension, and heart failure. The sales-heavy hiring mix (28 roles vs. 10 manufacturing, 8 engineering) reflects a commercialization-stage company scaling field coverage; active projects center on formulary access, practice pathway integration, and clinical-to-customer communication—indicating the core friction point is not R&D but market adoption and provider education.

Tech Stack 28 technologies

Core StackSmartsheet Asana AutoCAD Power BI HPLC GCP Excel Word PowerPoint McAfee Microsoft 365 Configuration Manager Ghost Teams SharePoint Entra Adobe Apple Veeva CRM UPLC Microsoft Office SharePoint Online Microsoft Project Outlook TM1 Articulate 360 Adobe Captivate SCORM

What MannKind Corporation Is Building

◆Challenges

Increasing product utilization
Practice pathway friction
Pull-through strategies
Meeting sales budgets
Hardware and software inventory management
Meeting territory sales targets
Maintaining glp compliance
Sales growth
Solving customer challenges translating clinical data
Barriers to access

▲Active Projects

Afrezza commercial growth in idns, amcs, and pediatric endocrinology centers
Gcp/pv external audit program
Speaker programs
Integration of furoscix into treatment protocols
Technology transfer to commercial manufacturing
Pull-through strategy for formulary access
Regulatory operations process improvement
Strategic territory plans
Patient services program
Protocol & pathway integration for afrezza

Hiring Activity

Steady65 roles · 20 in 30d

Department

Sales

Manufacturing

Engineering

Healthcare

Ops

Legal

Marketing

Research

Seniority

Mid

Senior

Intern

Manager

Junior

Director

Notable leadership hires: Regional Sales Director, Sales Director

Company intelligence

Find more companies like MannKind Corporation by tech stack, pain points and active projects

Get started free

About MannKind Corporation

MannKind develops and commercializes inhalable therapies addressing chronic diseases with unmet medical needs. The company operates across cardiometabolic diseases (including diabetes) and orphan lung indications (pulmonary hypertension, heart failure, chronic kidney disease). Core products include Afrezza (inhalable insulin) and Furoscix (inhalable diuretic), positioned as patient-friendly alternatives to injections and infusions. Operations span regulatory affairs, manufacturing, sales, and patient services, with headquarters in Danbury, CT and approximately 500–1,000 employees.

HeadquartersDanbury, CT

Company Size501–1,000 employees

Hiring MarketsUnited States

Frequently Asked Questions

What is MannKind Corporation's main product?

MannKind commercializes inhalable therapies, including Afrezza (inhalable insulin for diabetes) and Furoscix (inhalable diuretic for heart failure and chronic kidney disease). Both are drug-device combinations designed for chronic disease management.

What tech does MannKind use?

Core stack includes Veeva CRM (pharma-specific), GCP, Power BI, Microsoft 365, Asana, and lab instruments (HPLC, UPLC). No recent tech adoptions or replacements noted in hiring signals.